Caricamento...
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
Targeted cancer therapies often induce “outlier” responses in molecularly defined patient subsets. One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years. Whole-genome sequencing and RNA s...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Clinical Investigation
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3973082/ https://ncbi.nlm.nih.gov/pubmed/24569458 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI72763 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|